Immunitybio Inc (IBRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.40B
Last updated: Nov 17, 2026 at 4:43 PM ET
Immunitybio Inc (IBRX) Statistics
Immunitybio (IBRX) has a market cap of $6.40B and an enterprise value of $7.62B. It kept -454.49% of revenue as net income over the last 12 months. Revenue grew 149.99% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 18.99% above the market cap, as debt exceeds cash.
| Market Cap | $6.40B |
|---|---|
| Enterprise Value | $7.62B |
| Latest price (Nov 17, 2026) | $6.26 |
Key Dates
The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 31.8x. Its year-end P/S ranged from 13.3x to 550.1x from 2019 to 2025.
| P/S Ratio | 31.8x |
|---|---|
| Forward P/S | 32.0x |
Price Statistics
The stock is up 200.96% over 52 weeks and trades 26.44% below its 50-day average.
| Beta (1Y) | 1.40 |
|---|---|
| 52-Week Change | +200.96% |
| 1-Month Change | -25.65% |
| 3-Month Change | -23.00% |
| 6-Month Change | -19.33% |
| 5-Year Change | +5.87% |
| 10-Year Change | +38.40% |
| Total Return (1Y) | +200.96% |
| Total Return (3Y CAGR) | +14.77% |
| Total Return (5Y CAGR) | -0.84% |
| Return vs SPY (1Y) | +186.54% |
| Max Drawdown (1Y) | -48.23% |
| Max Drawdown (3Y) | -79.34% |
| Sharpe Ratio (1Y) | 1.05 |
| Correlation with SPY (1Y) | 0.19 |
| 50-Day Average | $8.51 |
| 200-Day Average | $7.97 |
| 52-Week Range | $1.95 to $12.43 |
| RSI (14 Days) | 35.7 |
| Average Volume (20 Days) | 12.87M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.27x current liabilities.
| Current Ratio | 4.27x |
|---|---|
| Quick Ratio | 4.27x |
| Interest Coverage | -10.06x |
Returns and Efficiency
Return on invested capital is -780.52% over the last 12 months.
| Return on Assets (ROA) | -155.87% |
|---|---|
| Return on Invested Capital (ROIC) | -780.52% |
| Return on Capital Employed (ROCE) | -175.60% |
| ROA (5Y Average) | -96.71% |
| Asset Turnover | 0.37x |
| Inventory Turnover | 1.95x |
| Receivables Turnover | 3.90x |
| Cash Conversion Cycle | -7813 days |
Scores
IBRX has an Altman Z-Score of -12.59, in the distress zone below 1.81, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -12.59 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $209.00M over the last 12 months.
| Revenue | $209.00M |
|---|---|
| Revenue Growth (YoY) | +149.99% |
| Gross Profit | $207.10M |
| Operating Income | -$147.24M |
| Pretax Income | -$950.22M |
| Net Income | -$949.86M |
| EBIT | -$897.83M |
| Reported EPS (TTM) | -$0.32 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $45.08M |
|---|---|
| Total Debt | $1.26B |
| Net Debt | $1.22B |
| Net Debt Per Share | $1.15 |
| Working Capital | $320.70M |
| Shareholder Equity | -$1.15B |
| Tangible Book Value | -$1.16B |
| Total Assets | $609.39M |
| Total Liabilities | $1.75B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $9.56M of capital spending, operating cash flow left -$297.13M of free cash flow.
| Operating Cash Flow | -$287.56M |
|---|---|
| Capital Expenditures | $9.56M |
| Free Cash Flow | -$297.13M |
| FCF Per Share | -$0.28 |
| Depreciation and Amortization | $24.69M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -70.45%.
| Gross Margin | 99.09% |
|---|---|
| Operating Margin | -70.45% |
| Pretax Margin | -454.66% |
| Net Margin | -454.49% |
| EBIT Margin | -429.59% |
| FCF Margin | -142.17% |
| Gross Margin (5Y Average) | 99.87% |
Growth
Revenue grew 678.62% a year over 3 years.
| Revenue Growth (3Y CAGR) | +678.62% |
|---|---|
| Revenue Growth (5Y CAGR) | +184.76% |
Dividends and Yields
IBRX does not pay a dividend. Its free cash flow yield is -4.48%.
| FCF Yield | -4.48% |
|---|---|
| Buyback Yield | -1.24% |
| Shareholder Yield | -1.24% |
Peer Position
Against 4 similar companies, IBRX has the 2nd highest P/S.
P/S RatioPeer median 10.1x
ROICPeer median -43.38%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +39.49%
| P/S Ratio | 31.8x vs 10.1x median |
|---|---|
| ROIC | -780.52% vs -43.38% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +149.99% vs +39.49% median |
Analyst Forecast
Consensus estimates put revenue growth at 100.41% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +100.41% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About IBRX
What is IBRX's market cap?
Immunitybio has a market cap of $6.40B. Its enterprise value, which adds debt and subtracts cash, is $7.62B.
How many shares of IBRX are outstanding?
Immunitybio has 1.06B shares outstanding. The count is up 12.00% from a year earlier.
Does IBRX pay a dividend?
No. Immunitybio does not pay a dividend.
How much debt does IBRX have?
Immunitybio has $1.26B of total debt and $45.08M of cash and equivalents, a net debt position of $1.22B.
IBRX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors